Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease

ME Seifert, L De Las Fuentes, M Rothstein… - American journal of …, 2013 - karger.com
Abstract Background/Aims: Cardiovascular disease (CVD) is increased in chronic kidney
disease (CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD …
被引用次数：86 相关文章

Effects of Phosphate Binder Therapy on Vascular Stiffness in Early-Stage Chronic Kidney Disease

ME Seifert, L De Las Fuentes… - American Journal of …, 2013 - search.proquest.com
Background/Aims: Cardiovascular disease (CVD) is increased in chronic kidney disease
(CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD-MBD begins …

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease

ME Seifert, L de las Fuentes, M Rothstein, DJ Dietzen… - 2013 - pubmed.ncbi.nlm.nih.gov
Background/aims Cardiovascular disease (CVD) is increased in chronic kidney disease
(CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD-MBD begins …

[引用][C] Effects of Phosphate Binder Therapy on Vascular Stiffness in Early-Stage Chronic Kidney Disease

ME Seifert, L de las Fuentes, M Rothstein… - American Journal of …, 2013 - cir.nii.ac.jp

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.

ME Seifert, L de las Fuentes, M Rothstein… - American Journal of …, 2013 - europepmc.org
Methods We randomized 38 subjects with normophosphatemic stage 3 CKD to a fixed dose
of LaCO3 or matching placebo without adjusting dietary phosphorus in a 12-month …

Effects of Phosphate Binder Therapy on Vascular Stiffness in Early-Stage Chronic Kidney Disease

ME Seifert, L de Las Fuentes, M Rothstein… - American Journal of …, 2013 - hero.epa.gov
Background/Aims: Cardiovascular disease (CVD) is increased in chronic kidney disease
(CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD-MBD begins …

Effects of Phosphate Binder Therapy on Vascular Stiffness in Early-Stage Chronic Kidney Disease.

ME Seifert, L de las Fuentes… - American Journal of …, 2013 - search.ebscohost.com
Abstract Background/Aims: Cardiovascular disease (CVD) is increased in chronic kidney
disease (CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD …

Effects of Phosphate Binder Therapy on Vascular Stiffness in Early-Stage Chronic Kidney Disease

ME Seifert, L de las Fuentes, M Rothstein… - American Journal of …, 2013 - karger.com
Background/Aims: Cardiovascular disease (CVD) is increased in chronic kidney disease
(CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD-MBD begins …

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease

ME Seifert, L De Las Fuentes, M Rothstein… - American Journal of …, 2013 - profiles.wustl.edu
Background/Aims: Cardiovascular disease (CVD) is increased in chronic kidney disease
(CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD-MBD begins …
[HTML] nih.gov

[HTML][HTML] Effects of Phosphate Binder Therapy on Vascular Stiffness in Early Stage Chronic Kidney Disease

ME Seifert, L de las Fuentes, M Rothstein… - American journal of …, 2013 - ncbi.nlm.nih.gov
Methods We randomized 38 subjects with normophosphatemic stage 3 CKD to a fixed dose
of LaCO3 or matching placebo without adjusting dietary phosphorus in a 12-month …